T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

Clinical trial NCT07683754 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07683754
Sponsor: Daiichi Sankyo
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Breast Cancer Metastatic Breast Cancer HER2 Positive HR Positive

Start date: 2026-09-04
Primary completion: 2030-07-04
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.